Branched-chain alpha-keto acid dehydrogenase complex
The branched-chain alpha-keto acid dehydrogenase complex (BCKDC) is a multi-enzyme complex that plays a crucial role in the catabolism of branched-chain amino acids (BCAAs) such as leucine, isoleucine, and valine. This complex is responsible for the oxidative decarboxylation of branched-chain alpha-keto acids, which are derived from the transamination of BCAAs.
Structure[edit]
The BCKDC is a large, multi-subunit complex composed of multiple copies of three catalytic components:
1. E1 component: Branched-chain alpha-keto acid dehydrogenase (BCKD), which requires thiamine pyrophosphate (TPP) as a cofactor. 2. E2 component: Dihydrolipoyl transacylase, which contains a lipoamide "swinging arm" that transfers acyl groups. 3. E3 component: Dihydrolipoamide dehydrogenase, which uses FAD and NAD+ as cofactors to regenerate the oxidized form of lipoamide.
Function[edit]
The primary function of the BCKDC is to catalyze the conversion of branched-chain alpha-keto acids into their corresponding acyl-CoA derivatives, which can then enter the citric acid cycle or be used in other metabolic pathways. This reaction is a key step in the catabolism of BCAAs, which are essential amino acids that must be obtained from the diet.
Catalytic Mechanism[edit]
The catalytic mechanism of BCKDC involves several steps:
1. Decarboxylation: The E1 component catalyzes the decarboxylation of the alpha-keto acid, forming an acyl-TPP intermediate.
2. Acyl transfer: The acyl group is transferred to the lipoamide "swinging arm" of the E2 component, forming an acyl-lipoamide intermediate.
3. CoA transfer: The acyl group is transferred from the lipoamide to CoA, forming acyl-CoA. 4. Regeneration: The E3 component regenerates the oxidized form of lipoamide, using FAD and NAD+ as cofactors.
Regulation[edit]
The activity of BCKDC is tightly regulated by phosphorylation and dephosphorylation. The complex is inactivated by phosphorylation of the E1 component by a specific kinase, and reactivated by dephosphorylation by a specific phosphatase. This regulation allows the cell to control the breakdown of BCAAs according to metabolic needs.
Clinical Significance[edit]
Deficiencies in BCKDC activity can lead to metabolic disorders such as maple syrup urine disease (MSUD), which is characterized by the accumulation of branched-chain amino acids and their corresponding keto acids in the blood and urine. MSUD can lead to neurological damage and other severe symptoms if not managed properly.
Also see[edit]
- Branched-chain amino acid metabolism
- Maple syrup urine disease
- Citric acid cycle
- Amino acid catabolism
 | This enzyme-related article is a stub. You can help WikiMD by expanding the page. |
| Metabolism, catabolism, anabolism | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
